RE: Polarised BB29 Aug 2023 09:09
Mr Budd's and BoD's strategy is to continue to raise funds each year and to do this without sales they need to develop products that are COULD BECOME revolutionary eg POC covid test, stroke marker . This is jso that AIHL, GDR flagship and most developed product, can continue to plod along awaiting sales and further test results over the next 3 years , at least. For ii 's to fund GDR, the SP doesn't necessarily need to increase but volumes do , hence a hyped product needs to be in development, GDR doesn't necessarily need to produce this hyped product , let alone achieve certification or sales, it just needs to produce a potentially ground-breaking product. This fund raising strategy is not unique to GDR but many pharma companies imo. For example, a few weeks ago a company from Scotland hit the news with a potentially ground breaking test for Alzheimers. They hadn't produced the product but its in development. This sort of story is click-bait and, if a company is listed, click-bait results in a temporary increase in SP which in turn can be taken advantage of by the company to raise funds. However, GDR's problem this year is the deal with RF will prevent any other ii's funding GDR - no ii will enter a deal with a company who is part of a death spiral finance deal as the debt to RF needs to be serviced first. Currently, I can't work out how GDR will raise funding again with the RF circling GDR from above. Hence for me this is a sell, so as they say on Dragons Den, I'm out.